Our History

Cipla has over 8 decades of caring for life!

1935-1960
1961-1975
1976-2011
2012-2018
2019
2020
1935-1960

1935 - 1960

Esteemed dignitaries visit CIPLA - Sardar Vallabhbhai Patel, Sushila Nayyar, Shanti Swarup Bhatnagar, Ramaswamy Mudaliar, Amrit Kaur, Gulzarilal Nanda, Morarji Desai, Sir C.V. Raman, Crown Prince Fazl of Saudi Arabia, Rafi Ahmed Kidwai, Mohd. Asaf Ali and Maulana Azad

1947

CIPLA celebrates India attaining Independence with flag hoisting ceremony at Mumbai Central Headquarters

1948

CIPLA's advertisement features in the 1948 edition of the MARG journal

1954

CIPLA exhibits at the All India Medical Conference 

1957-1958

CIPLA cricket team wins the E-Merck shield

1961-1975

1968

CIPLA's turnover crosses the 1 crore mark.

1976-2011

1979

Installation of an ORG 2001 computer at Mumbai Central Headquarters to ease the process of  financial accounts and pay rolls, saving 20 days labour of seven persons.

1984

Inauguration of Patalganga manufacturing plant

1991

Cipla's turnover crosses Rs. 100 crores

2012-2018

2016

At the 21st International AIDS Conference in Durban, Cipla organises the 'Durban to Durban Forum' - a unique session wherein Dr. Y.K. Hamied delivered a speech marking Cipla's 16-year journey in fighting HIV/AIDS

2016

Cipla shifts to professional management and announces its new Management Council

2016

Cipla Health Ltd. is established with a vision of becoming the most preferred consumer healthcare company in India

2017

Cipla launches Synchrobreathe, a state of the - art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.

2017

Cipla Palliative Care and Training Centre (CPC) marks its 20th anniversary, with a special program organised by the Cipla Patalganga team

2019

2019

Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.

2019

Cipla USA furthers AMR stewardship with acquisition of key anti-infective ZEMDRI™

2020

2020

In continuance of its efforts to advance quality education and promote industry-academia collaboration, Cipla Foundation, funds the set-up of a world class chemistry research laboratory at the Indian Institute of Science Education and Research (IISER) Pune.

2020

Cipla receives Great Place To Work Certification once again.

2020

Cipla receives final approval for generic version of Proventil® HFA Inhalation Aerosol (Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation)

2020

Cipla Foundation supports the set up of Maharashtra's only dedicated pediatric isolation ward for COVID-19

2020

Cipla - Breathe Free Lanka Pvt Ltd. receives Great Place To Work certification. Cipla is one of the top 3 pharma companies in Sri Lanka

2020

Cipla Foundation reaches out to local communities affected by Cyclone Amphan in West Bengal, India by providing essential hygeine and food supplies to those in need.

2020

In June 2020, Cipla Foundation South Africa together with Miltons Matsemela hosted a virtual Youth Day Run to raise funds for frontline COVID healthcare workers.

2020

Cipla signs a distribution agreement with Roche Products (India) Pvt. Ltd. to expand scope of the partnership to include, marketing and distribution of Roche’s trademark oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India

2020

Cipla launches remdesivir under its brand name CIPREMI. In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s generic version of remedisvir called CIPREMI.

2020

Cipla and Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs - Oboravo® (Empagliflozin), Oboravo Met® (Empagliflozin+Metformin) and Tiptengio® (Empagliflozin+Linagliptin)

2020

Cipla is granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in India under the brand name Ciplenza. Favipiravir is an off patent, oral anti-viral drug that has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms.

2020

Cipla completes 85 years on 17th August 2020.

2020

Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI).